mRNA cancer vaccine Phase 3 trial
-
Moderna Stock Surges 177% as mRNA Melanoma Vaccine with Merck Succeeds in Phase 3 Trial
Moderna and Merck’s personalized mRNA cancer vaccine, Intismeran, combined with Keytruda, met key endpoints in a Phase 3 melanoma trial, adding $44 billion to Moderna’s market value in a day.
intismeran autogene, Keytruda and Moderna vaccine combination, melanoma vaccine, Merck stock (MRK), Moderna cancer vaccine, Moderna news today, Moderna stock, mRNA cancer vaccine Phase 3 trial, MRNA stock price, personalized cancer treatment, skin cancer breakthrough 2026